同位素2025，Vol.38Issue(2)：195-205,11.DOI:10.7538/tws.2024.youxian.093
89Zr标记单克隆抗体药物的研究进展
The Research Progress of Monoclonal Antibody Labeled with 89Zr
肖展雄 1段菲 1李洪玉1
作者信息
- 1. 国家原子能机构核技术(放射性药物工程转化)研发中心,北京 102413||中核集团放射性药物工程技术研究中心,北京 102413||原子高科股份有限公司,北京 102413
- 折叠
摘要
Abstract
Zirconium-89(89Zr)is a metallic positron-emitting radionuclide.The relatively long half-life and moderate energy making 89Zr especially suitable for the labeling of large biomolecules such as antibodies for radioimmuno-PET(positron emission tomography)imaging.In recent years,significant progress has been made in the research of 89Zr-labeled monoclonal antibodies(mAbs),driven by the development of mAb therapies.Currently,some of these mAb drugs have entered clinical phases II and III.In the labeling methods of 89Zr,deferoxamine B(DFO)is the most commonly used chelator and has been applied in clinical research.However,researchers are still continually exploring better ligands.In terms of chelator-mAb conjugation techniques,various forms of DFO derivatives remain the primary focus of research.In this article,89Zr labeling methods,chelator conjugation techniques,and advances in 89Zr-mAbs were reviewed.The challenges,issues,and future trends of 89Zr-mAbs has also been discussed and prospected.关键词
89Zr/单克隆抗体/正电子发射断层显像(PET)Key words
89Zr/monoclonal antibody/PET分类
能源科技引用本文复制引用
肖展雄,段菲,李洪玉..89Zr标记单克隆抗体药物的研究进展[J].同位素,2025,38(2):195-205,11.
